These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

151 related articles for article (PubMed ID: 27159045)

  • 1. Insulin amyloid at injection sites of patients with diabetes.
    Nilsson MR
    Amyloid; 2016 Sep; 23(3):139-147. PubMed ID: 27159045
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Diabetes drug update: how 4 new options stack up.
    Taylor JR; Campbell KM
    J Fam Pract; 2007 Mar; 56(3):207-15. PubMed ID: 17343811
    [No Abstract]   [Full Text] [Related]  

  • 3. Human recombinant insulin and amyloidosis: an unexpected association.
    Sie MP; van der Wiel HE; Smedts FM; de Boer AC
    Neth J Med; 2010 Mar; 68(3):138-40. PubMed ID: 20308712
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Nodular amyloidosis at the sites of insulin injections.
    Bernárdez C; Schärer L; Molina-Ruiz AM; Requena L
    J Cutan Pathol; 2015 Jul; 42(7):496-502. PubMed ID: 25953111
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Pharmaceutical amyloidosis associated with subcutaneous insulin and enfuvirtide administration.
    D'Souza A; Theis JD; Vrana JA; Dogan A
    Amyloid; 2014 Jun; 21(2):71-5. PubMed ID: 24446896
    [TBL] [Abstract][Full Text] [Related]  

  • 6. New Histologic Finding of Amyloid Insulin Bodies at an Insulin Injection Site in a Patient With Diabetes.
    Katzman BD; Traum P; Medline PB
    Am J Dermatopathol; 2018 Jul; 40(7):527-530. PubMed ID: 29135508
    [TBL] [Abstract][Full Text] [Related]  

  • 7. No sign of amyloidosis in pump-treated diabetics.
    Regal H; Koivisto VA; Maury CP; Irsigler K
    Diabetes Res; 1988 Aug; 8(4):195-9. PubMed ID: 3069282
    [TBL] [Abstract][Full Text] [Related]  

  • 8. An abdominal wall mass of exogenous insulin amyloidosis in setting of metastatic sarcoma.
    Carll T; Antic T
    J Cutan Pathol; 2020 Apr; 47(4):406-408. PubMed ID: 31721261
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Continuous subcutaneous insulin infusion therapy: A primer on insulin pumps.
    Potti LG; Haines ST
    J Am Pharm Assoc (2003); 2009; 49(1):e1-13; quiz e14-7. PubMed ID: 19196588
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pediatrics, Pens, and Pumps.
    Hieronymus L; Hepner A; Cherolis J
    Diabetes Self Manag; 2015; 32(2):20-3. PubMed ID: 26665831
    [No Abstract]   [Full Text] [Related]  

  • 11. Localized amyloidosis at the site of repeated insulin injection in a diabetic patient.
    Shikama Y; Kitazawa J; Yagihashi N; Uehara O; Murata Y; Yajima N; Wada R; Yagihashi S
    Intern Med; 2010; 49(5):397-401. PubMed ID: 20190472
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Current insight in the localized insulin-derived amyloidosis (LIDA): clinico-pathological characteristics and differential diagnosis.
    Ansari AM; Osmani L; Matsangos AE; Li QK
    Pathol Res Pract; 2017 Oct; 213(10):1237-1241. PubMed ID: 28935176
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Localized insulin-derived amyloidosis: a potential pitfall in the diagnosis of systemic amyloidosis by fat aspirate.
    D'Souza A; Theis JD; Vrana JA; Buadi F; Dispenzieri A; Dogan A
    Am J Hematol; 2012 Nov; 87(11):E131-2. PubMed ID: 23044893
    [No Abstract]   [Full Text] [Related]  

  • 14. Review of phase 2 studies utilizing the AIR particle technology in the delivery of human insulin inhalation powder versus subcutaneous regular or lispro insulin in subjects with type 1 or type 2 diabetes.
    Ellis SL; Gemperline KA; Garg SK
    Diabetes Technol Ther; 2007 Jun; 9 Suppl 1():S48-56. PubMed ID: 17563304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Severe insulin resistance associated with subcutaneous amyloid deposition.
    Albert SG; Obadiah J; Parseghian SA; Yadira Hurley M; Mooradian AD
    Diabetes Res Clin Pract; 2007 Mar; 75(3):374-6. PubMed ID: 16930758
    [TBL] [Abstract][Full Text] [Related]  

  • 16. New concepts in diabetes: how multihormonal regulation can improve glycemic control.
    Blonde L; Baker DE; Davis SN; Ratner RE
    J Manag Care Pharm; 2004 Dec; 10(6 Suppl B):S3-8; quiz S9, S11-2. PubMed ID: 23570175
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Use of rapid-acting insulin analogues in the treatment of patients with type 1 and type 2 diabetes mellitus: insulin pump therapy versus multiple daily injections.
    Bode BW
    Clin Ther; 2007; 29 Suppl D():S135-44. PubMed ID: 18191065
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Noninjectable methods of insulin administration.
    Cernea S; Raz I
    Timely Top Med Cardiovasc Dis; 2006 Nov; 10():E29. PubMed ID: 17136235
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Risks and side effects of intensified insulin therapy].
    Honegger R; Spinas GA
    Wien Med Wochenschr; 1997; 147(9):226-30. PubMed ID: 9281237
    [TBL] [Abstract][Full Text] [Related]  

  • 20. In pursuit of excellence in diabetes care: trends in insulin delivery.
    Meetoo D; McAllister G; West A; Turnbull M
    Br J Nurs; 2012 May 24-Jun 13; 21(10):588-92, 594-5. PubMed ID: 22875294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.